Ningbo Menovo Pharmaceutical Co., Ltd.

Ningbo Menovo Pharmaceutical Co., Ltd. faced a notable decline in its stock today, contrasting with a slight gain in the broader market. Despite recent setbacks, the company reported strong financial metrics, including increased net sales and efficient receivables management, while maintaining a significant year-over-year performance.

Ningbo Menovo Pharmaceutical Co., Ltd. saw a significant stock decline today, contrasting with the broader market's performance. Despite this downturn, the company has achieved impressive annual growth and year-to-date gains. Financial metrics indicate moderate debt levels but limited profitability, with mixed trends in sales and operating profit over five years.

Ningbo Menovo Pharmaceutical Co., Ltd. saw a notable rise in its stock price on July 10, 2026, reaching an intraday high. The company has outperformed the market over various timeframes, achieving significant annual returns. However, it faces challenges like a high debt-to-equity ratio and modest long-term growth prospects.

Ningbo Menovo Pharmaceutical Co., Ltd. has seen notable stock activity, achieving a significant intraday high. Over the past year, the company has outperformed market averages, despite facing challenges in long-term growth. Recent financial metrics indicate positive trends, including reduced raw material costs and a strong debtors turnover ratio.

Ningbo Menovo Pharmaceutical Co., Ltd. saw a notable rise in stock performance today, contrasting with the broader market. Despite recent challenges, the company has shown strong year-to-date growth and outperformed the market over the past year. Key financial metrics indicate increasing net sales and a stable return on equity.

Ningbo Menovo Pharmaceutical Co., Ltd. saw a notable decline in its stock today, contrasting with the broader market's modest decrease. Despite recent downturns, the company has achieved impressive annual returns and strong year-to-date performance, although it faces challenges in long-term growth and profitability metrics.

Ningbo Menovo Pharmaceutical Co., Ltd. saw a significant stock decline today, contrasting with the modest gain of the China Shanghai Composite. Despite a recent weekly increase, the stock has faced challenges, including a notable monthly decrease and financial pressures reflected in its profitability metrics and debt-to-equity ratio.

Ningbo Menovo Pharmaceutical Co., Ltd. experienced notable intraday gains, contrasting with a decline in the broader market. Over the past year, the company has significantly outperformed the market, although it faces challenges in long-term growth. Recent financial metrics show positive trends, including increased net sales and a strong debtors turnover ratio.

Ningbo Menovo Pharmaceutical Co., Ltd. saw an 8.8% decline in stock price today, contrasting with a gain in the China Shanghai Composite. Despite a significant year-over-year increase of 214.42%, the company faces challenges such as a moderate return on equity and a notable debt-to-equity ratio.

Ningbo Menovo Pharmaceutical Co., Ltd. saw a significant stock decline today, contrasting with a slight increase in the China Shanghai Composite. Despite recent downturns, the company has achieved substantial growth over the past year and three years, maintaining a market capitalization of CNY 10,727 million and a moderate return on equity.

Ningbo Menovo Pharmaceutical Co., Ltd. has shown remarkable stock performance, rising significantly over the past week and month, while the broader market has declined. Despite challenges such as a moderate debt-to-equity ratio, the company has reported improvements in net sales and reduced raw material costs, highlighting its strong short-term metrics.

Ningbo Menovo Pharmaceutical Co., Ltd. has shown remarkable stock performance, significantly outperforming the broader market. Over the past week, the stock has increased by over 40%, with substantial gains year-to-date and over the past year. The company is navigating challenges while demonstrating positive financial trends.

Ningbo Menovo Pharmaceutical Co., Ltd. has shown remarkable short-term stock performance, rising significantly today and over the past week and month, while the broader market has declined. Despite strong quarterly sales and a positive year-to-date performance, the company faces challenges with long-term growth and modest annual sales increases.

Ningbo Menovo Pharmaceutical Co., Ltd. has shown impressive stock performance, gaining 10.02% on March 13, 2026, and achieving a 56.90% return over the past year. The company maintains a manageable debt-to-equity ratio of 0.37 and demonstrates effective receivables management with a turnover ratio of 4.99 times.

Ningbo Menovo Pharmaceutical Co., Ltd. saw a notable increase in stock performance, reaching an intraday high and outperforming the broader market over the past year. The company has a market capitalization of CNY 4,472 million, with solid financial metrics, including a manageable debt-to-equity ratio and a competitive dividend yield.